Bayer Pharma to Launch New Drugs, Expanding Cardiology & Women's Health

Bayer has declared that the company is gearing up for market launch this year about the two newer drugs for its cardiology and women's health portfolios for its pharmaceuticals business in a high-profile debt situation.

The company further expanded upon its extensive investments in R&D adding further impetus to medical innovation and raising highly differentiated pipelines in oncology, cardiovascular diseases, neurology, rare diseases, and immunology.

The cell and gene therapy platform for Parkinson's disease is being advanced by Bayer through the achievement of important clinical milestones. Further strategic evaluation and prioritization of the pipeline are underway, concentrating on the very highest-quality programs addressing critical unmet medical needs.

The leadership group has expressed an intention to grow the cardiology portfolio with the introduction of treatment for Transthyretin Amyloid Cardiomyopathy in Europe. Specifically, Bayer intends to introduce a heart failure treatment for patients with a left ventricular ejection fraction of 40 or more by the year 2025.

In women's health, Bayer is preparing to launch an innovative hormone-free therapy for the treatment of moderate-to-severe vasomotor symptoms during menopause. In parallel, a new drug for use in patients with hormone-sensitive metastatic prostate cancer is also expected to be added to the oncology therapy, consolidating Bayer's leadership in the field.

These commitments underline the innovations that Bayer is pursuing for the growth of providing potential medicines for long-term therapeutics.

Christine Roth, Executive Vice President, Global Product Strategy and Commercialization and Member of the Pharmaceuticals Leadership Team at Bayer said, "We are shaping a new era of medicine, confident that we can not only transform patient care through breakthrough innovation and a robust product portfolio, but also by accelerating patient access to new medicines. With every new development, we are getting one step closer to realizing our vision to treat the untreatable, cure disease and offer hope".